---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-090842"
form_type: "8-K"
ticker: "ADGM"
cik: "0002006986"
company_name: "Adagio Medical Holdings, Inc."
filed_at: "2024-08-19T23:59:59+00:00"
generated_at: "2026-05-31T08:44:33.705887+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adagio Medical obtains CE Mark for VT catheter, closes business combination with $35M pro forma cash

## Summary
- CE Mark approval and commercial launch of vCLAS catheter for ventricular tachycardia in select European markets.
- FDA approved FULCRUM-VT pivotal IDE study for VT cryoablation system; patient enrollment starts September 2024.
- Closed business combination with ARYA Sciences Acquisition Corp; shares listed on Nasdaq under ADGM on Aug 1, 2024.
- Raised approx. $84.2M from trust, PIPE, and convertible financing; pro forma cash ~$35M after transaction costs.

## SEC filing metadata
- accession: 0001104659-24-090842
- form_type: 8-K
- ticker: ADGM
- cik: 0002006986
- company_name: Adagio Medical Holdings, Inc.
- filed_at: 2024-08-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2006986/000110465924090842/0001104659-24-090842-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2006986/000110465924090842/tm2422065d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-090842
- JSON: https://secwatch.observer/filing/0001104659-24-090842.json
- Plain text: https://secwatch.observer/filing/0001104659-24-090842.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.